Insight

Adjuvant GemCis vs CRT with capecitabine in gallbladder cancer

Photo taken from dreamstime.com

Jul 7, 2024, 07:19

Adjuvant GemCis vs CRT with capecitabine in gallbladder cancer

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:

“Adjuvant GemCis (gemcitabine and cisplatin) vs CRT (chemoradiotherapy) with capecitabine in gallbladder cancer GECCOR-GB study in JAMA Oncology.

Phase II
Resected stage II/III

R0 or R1 1-year DFS: %88.9 vs 77.8%
2-year DFS: 74.8% vs 74.8%
Completion of planned trratment: 82% vs 62%
Both met primary endpoint of 1-y DFS 77%“

Proceed to the study.
Source: Erman Akkus/X

Adjuvant GemCis Ankara University cancer capecitabine chemoradiotherapy CRT Erman Akkus gallbladder cancer GECCOR-GB study gemcitabine and cisplatin JAMA Oncology OncoDaily Oncology

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage